IN BRIEF: RTW funds investee Ji Xing to develop drug with Milestone

RTW Venture Fund Ltd - investment company focused on the life sciences sector - Participates in a ...

Alliance News 15 July, 2021 | 8:35AM
Email Form Facebook Twitter LinkedIn RSS

RTW Venture Fund Ltd - investment company focused on the life sciences sector - Participates in a Series B financing round for portfolio company Ji Xing Pharmaceuticals, a Chinese biotechnology business. Expects the new capital to fund Ji Xing's operations and commitments to its licensing partners. Alongside other investors, RTW says it seeded Ji Xing in February 2020 and completed a Series A funding round in July 2020.

Notes Joseph Romanelli has been appointed as Ji Xing's chief executive and as a member of the board of directors. Notes Romanelli has over 25 years of biotechnology experience, mostly with US-based pharmaceutical company Merck & Co Inc.

Says Ji Xing has agreed an exclusive licencing agreement with another RTW portfolio company, cardiovascular biopharmaceutical firm Milestone Pharmaceuticals Inc. The pair will collaborate to develop, and potentially commercialise, etripamil in greater China. Etripamil is a nasal medication for patients with paroxysmal supraventricular tachycardia, a condition that causes abnormal heartbeat.

Current RTW stock price: USD2.06

Year-to-date change: up 9.5%

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
RTW Venture Ord 1.86 USD -0.27 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.